Clinically and ethically relevant questions are related to patient safety, therapeutic efficacy, equitable access, and global governance over humanity’s genetic legacy.
AMA J Ethics. 2019;21(12):E1079-1088. doi:
10.1001/amajethics.2019.1079.
Gene editing reminds professionals and the public that this technology’s reach goes beyond treating somatic disease to germline consequences yet unknown.
AMA J Ethics. 2019;21(12):E1056-1058. doi:
10.1001/amajethics.2019.1056.
Dr Lisa M. Meeks joins Ethics Talk to discuss her article, coauthored with Dr Christopher Moreland: “How Should We Build Disability-Inclusive Medical School Admissions?”
Dr Dorothy W. Tolchin joins Ethics Talk to discuss her article, coauthored with Nicole D. Agaronnik, Shahin A. Saberi, and Dr Michael Ashley Stein: “Why Disability Must Be Included in Medical School Diversification Efforts”